Current understandings and perspectives on non-cancer health effects of benzene: A global concern by بهادر, حاجی et al.
Invited Review Article
Current understandings and perspectives on non-cancer health effects
of benzene: A global concern
Haji Bahadar a,b, Sara Mostafalou b, Mohammad Abdollahi b,⁎
a International Campus, Tehran University of Medical Sciences, Iran
b Pharmaceutical Sciences Research Center and Faculty of Pharmacy, Tehran University of Medical Sciences, Iran
a b s t r a c ta r t i c l e i n f o
Article history:
Received 28 November 2013
Revised 2 February 2014
Accepted 19 February 2014










Objective: Benzene, as a volatile organic compound, is known as one of the main air pollutants in the
environment. The aim of this review is to summarize all available evidences on non-cancerous health effects of
benzene providing an overview of possible association of exposure to benzene with human chronic diseases,
specially, in those regions of the world where benzene concentration is being poorly monitored.
Methodology: A bibliographic search of scientiﬁc databases including PubMed, Google Scholar, and Scirus was
conducted with key words of “benzene toxic health effects”, “environmental volatile organic compounds”,
“diabetes mellitus and environmental pollutants”, “breast cancer and environmental pollution”, “prevalence of
lung cancer”, and “diabetes prevalence”. More than 300 peer reviewed papers were examined. Experimental
and epidemiologic studies reporting health effects of benzene and volatile organic compounds were included
in the study.
Results: Epidemiologic and experimental studies suggest that benzene exposure can lead to numerous
non-cancerous health effects associatedwith functional aberration of vital systems in the body like reproductive,
immune, nervous, endocrine, cardiovascular, and respiratory.
Conclusion: Chronic diseases have become a health burden of global dimension with special emphasis in regions
with poor monitoring over contents of benzene in petrochemicals. Benzene is a well known carcinogen of blood
and its components, but the concern of benzene exposure is more than carcinogenicity of blood components
and should be evaluated in both epidemiologic and experimental studies. Aspect of interactions andmechanism
of toxicity in relation to human general health problems especially endocrine disturbances with particular
reference to diabetes, breast and lung cancers should be followed up.
© 2014 Elsevier Inc. All rights reserved.
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